What diseases is imatinib suitable for?

Imatinib (Imatinib), as a highly efficient targeted therapy drug, plays a pivotal role in the field of cancer treatment. It mainly shows significant therapeutic effects on the following diseases:

Imatinib is a powerful assistant in the treatment of chronic myelogenous leukemia (CML). CML is a blood system cancer caused by the BCR-ABL fusion gene. The gene product has abnormal tyrosine kinase activity, leading to unrestricted proliferation of leukemia cells. Imatinib can accurately inhibit BCR-ABL tyrosine kinase and block the proliferation signals of cancer cells, thereby effectively alleviating disease symptoms. It is especially suitable for patients with chronic phase CML and can also be used for the treatment of accelerated phase and blast phase.

Imatinib also performs well in the treatment of gastrointestinal stromal tumors (GIST). GIST is a tumor arising from the smooth muscle of the gastrointestinal tract and is often associated with mutations in the c-KIT gene. Imatinib slows down or prevents tumor growth by inhibiting the activity of c-KIT tyrosine kinase, providing new treatment hope for patients with recurrent or unresectable GIST after surgical resection.

Imatinib is also used to treat BCR-ABL fusion gene-positive acute lymphoblastic leukemia (ALL). There is an abnormal BCR-ABL tyrosine kinase in these patients. Imatinib can accurately target and inhibit this kinase to control the progression of the disease.

In addition to the above diseases, imatinib has also shown therapeutic potential in research and application for other cancers caused byBCR-ABL gene mutations. It improves the treatment of a variety of cancers caused by genetic mutations by specifically targeting and inhibiting abnormal tyrosine kinases, bringing longer survival and higher quality of life to patients.